Showing 2571-2580 of 5617 results for "".
- Colistin Resistance in Healthcare: Mechanisms and Managementhttps://reachmd.com/news/colistin-resistance-in-healthcare-mechanisms-and-management/2483530/In the battle against multidrug-resistant bacteria, colistin has emerged as a critical last-resort antibiotic. However, the rising tide of colistin resistance poses a significant threat to its efficacy, necessitating an urgent understanding of the underlying mechanisms and their clinical im
- Revance Announces CEO Transitionhttps://reachmd.com/news/revance-announces-ceo-transition/2475370/Revance announced a leadership transition last week as part of a long-term succession strategy following its integration with Crown Laboratories, according to a news release from the company. Founder and CEO of Crown Laboratories Jeff Bedard will assume the role of Executive Chai
- Polypharmacy Issues in Older Patients Concerning but Improvinghttps://reachmd.com/news/Polypharmacy-Issues-Older-Patients-Concerning-Improving/2474817/Geriatric medicine hinges on eight guiding principles, Freba Farhat, MD, said at the ElderDerm 2025 Conference in Washington, DC: life expectancy, multimorbidity, functional status, cognition, mobility, social support, patient preference, and polypharmacy. The last of those factors can sometimes
- Mini-Stroke: Prolonged Fatigue and Its Clinical Implicationshttps://reachmd.com/news/mini-stroke-prolonged-fatigue-and-its-clinical-implications/2474653/Transient ischemic attacks, known as mini-strokes, are traditionally seen as brief interruptions. Nonetheless, current findings indicate that such events might lead to extended fatigue lasting up to a year, urging clinicians to reevaluate their approach to post-event care.<
- Risk Factors and Postoperative Complications in Pulmonary Tuberculosishttps://reachmd.com/news/risk-factors-and-postoperative-complications-in-pulmonary-tuberculosis/2474576/Pulmonary tuberculosis (TB), long recognized as a persistent global health threat, is now drawing increasing attention for its complex implications in surgical care. Emerging clinical insights confirm that TB’s lasting effects on lung structure and function substan
- Loneliness Assessment: Evaluating Consistent Emotional and Cognitive Patternshttps://reachmd.com/news/loneliness-assessment-evaluating-consistent-emotional-and-cognitive-patterns/2474401/Despite the varied ways clinicians attempt to measure loneliness—be it how often a person feels isolated, how much distress it causes, or how long it lasts—new research suggests that the emotional and cognitive roots of the experience remain remarkably consistent.
- PN Therapeutic Pipeline Continues to Show Promisehttps://reachmd.com/news/PN-Therapeutic-Pipeline-Continues-Show-Promise/2471649/The US Food and Drug Administration (FDA) approval last year of nemolizumab for the treatment of adults with prurigo nodularis (PN) was likely only the beginning of a dramatically changing therapeutic landscape for that condition, Sonja Stander, MD, IFAAD, said at the 2025 American Academy of Der
- FDA Approves South Korean Neurotoxin for Frown Lineshttps://reachmd.com/news/fda-approves-south-korean-neurotoxin-for-frown-lines/2473751/The US Food and Drug Administration approved the neurotoxin, Letybo (letibotulinumtoxinA-wlbg), to treat moderate-to-severe glabellar lines in adults, Hugel Inc. announced last week. According to a press release, Hugel Inc. plans to accelerate its transition for approved medical use with
- Exploring Pulmonary Blood Flow Reduction in Pediatric Long COVIDhttps://reachmd.com/news/exploring-pulmonary-blood-flow-reduction-in-pediatric-long-covid/2471498/Recent research employing advanced PREFUL MRI techniques highlights significant reductions in lung blood flow among children and teenagers suffering from long COVID, offering new insights into the condition’s lasting impact on pediatric respiratory health.
- Galderma Seeks to Address Facial Volume Loss From GLP-1 Medications with Injectable Portfoliohttps://reachmd.com/news/new-datas-promising-results-to-predominant-aesthetic-concerns-for-prescription-weight-loss-medications/2473730/Galderma announced positive first results last week from a trial designed to explore the benefits of Restylane Lyft or Contour in combination with Sculptra in patients with medication-driven weight loss with associated facial volume loss. According to a press release from the manufacturer,